3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Head & Neck
26
Sarcoma
7
Gynecologic
6
Genitourinary
6
Gastrointestinal
6
Breast
6
Thoracic
5
Dermatologic
4
Endocrine
3
CNS
3
NET
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neuroendocrine Tumors
73
Carcinoma, Neuroendocrine
27
Pheochromocytoma
24
Thyroid Cancer, Papillary
23
Thyroid Neoplasms
21
Pituitary Neoplasms
21
Adrenocortical Carcinoma
19
Paraganglioma
16
Multiple Endocrine Neoplasia Type 1
14
Neuroblastoma
12
Sarcoma
11
Adenoma, Islet Cell
11
Small Cell Lung Carcinoma
10
Neoplasms
10
Melanoma
10
Lung Neoplasms
9
Carcinoid Tumor
9
Adrenal Gland Neoplasms
9
Adenocarcinoma, Follicular
9
Pancreatic Neoplasms
8
Gastro-enteropancreatic neuroendocrine tumor
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Medullary
8
Thyroid Carcinoma, Anaplastic
7
Neoplasm Metastasis
7
Mesothelioma
7
Cushing Syndrome
7
Cholangiocarcinoma
7
Central Nervous System Neoplasms
7
Breast Neoplasms
7
Interventions
entrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Endocrine
×
90 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02012699
2026-05-05
iCaRe2
University of Nebraska
Recruiting
999,999 enrolled
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA